Krystal Biotech is trading 10.1% down today at $306.65 after reporting second-quarter 2026 earnings where revenue slightly missed analyst expectations.
- VYJUVEK revenue grew 24% year-over-year to $119.2 million, though it fell short of consensus, while EPS of $1.79 beat estimates.
- The sharp pullback likely reflects profit-taking after a strong year-to-date run and investor disappointment regarding topline growth.
- Management reiterated its full-year guidance and highlighted its ongoing multi-product expansion strategy.